Company Overview of Alcyone Lifesciences, Inc.
Alcyone Lifesciences, Inc., a medical device company, focuses on development of novel treatment modalities for chronic neurological conditions. The company develops micro-fabricated delivery systems, including Alcyone MEMS (microelectromechanical system) Cannula (AMC) system, a neuro-ventricular cannula and accessories that enable neurosurgeons to select a target, navigate the AMC precisely to the target, and observe in real-time the precision delivery of the therapeutic agent under intra-procedural MRI guidance. It offers solutions for the treatment of various neurologic conditions, including brain tumor, hydrocephalus, epilepsy, and neurodegenerative diseases. The company was founded in 20...
250 Jackson Street
Unit 494 Mill No. 5 Building
Lowell, MA 01852
Founded in 2010
Key Executives for Alcyone Lifesciences, Inc.
Founder, Chief Executive Officer, President and Director
Co-Founder, Consulting Chief Medical Officer and Member of Scientific Advisory Board
Vice President of Regulatory, Quality and Clinical Affairs
Compensation as of Fiscal Year 2016.
Alcyone Lifesciences, Inc. Key Developments
Alcyone Lifesciences, Inc. Announces Clinical use of its ReFlow System for the Treatment of Hydrocephalus
Aug 2 16
Alcyone Lifesciences, Inc. has announced the clinical use of its ReFlow System in four patients treated to date in an institutional review board (IRB)-approved study at Boston Children's Hospital. Hydrocephalus is a condition in which an excess of cerebrospinal fluid (CSF) accumulates in the ventricles and can increase the pressure in the brain creating a life threatening condition. CSF shunts are implantable devices inserted by neurosurgeons to treat hydrocephalus. The youngest patients seem at high risk of shunt failure, many requiring numerous revision surgeries by adolescence. Alcyone's patented ReFlow™ System, comprised of a unique Flusher and Ventricular Catheter with relief membrane as components of a CSF shunt system, is designed to address one of the two most common and frustrating problems with CSF shunts resulting in emergency intervention, namely obstructions of the ventricular catheter. To extend the life of these shunts and avoid emergency shunt revision, retrograde flushing of flow regulating valves and invasive shunt taps have been employed by neurosurgeons in attempt to unblock ventricular catheters. However, these methods have been inconsistent, at best, and can introduce risk of infection (the other most common CSF shunt problem) and damage to the flow-regulating valve. The core concept to realize a fully implantable, non-invasive means that can consistently unblock an occluded ventricular catheter came from an earlier IRB study also performed at Boston Children's Hospital (BCH).
Alcyone Lifesciences, Inc. Presents at Boston CEO Conference, May-31-2016 03:30 PM
May 26 16
Alcyone Lifesciences, Inc. Presents at Boston CEO Conference, May-31-2016 03:30 PM. Venue: Four Seasons Boston, 200 Boylston Street, Boston, MA 02116, United States. Speakers: P. J. Anand, Founder, Chief Executive Officer, President and Director.
Nanologica, Alcyone Lifesciences to Collaborate Via Licensing Agreement
May 16 16
Nanologica announced that it has entered into a License and Collaboration Agreement with Alcyone Lifesciences to develop a novel therapeutic platform named Abela; 'to breathe' in Hebrew. The partners want to combine Nanologica's NLAB Silica™ with Alcyone's proprietary drug delivery platform technology. The goal is to develop and commercialize through partnership with biopharma a treatment of certain motor neuron disorders, including Amyotrophic Lateral Sclerosis (ALS), based on targeted and sustained delivery of trophic factors in combination with embryonic stem cell derived cells. The role of trophic factors is to rescue degenerating neurons or to support survival of transplanted stem cells in patients with ALS or other motor neuron disorders. According to the License and Collaboration Agreement, Alcyone will operate the Abela program and will be responsible for further development and financing of the program through collaboration with biopharma. ALS is a fatal neurodegenerative disease that affects nerve cells in the brain and spinal cord. It usually starts with loss of control of limbs or difficulties in swallowing related to muscle weakness. Most patients suffer a rapid decline in motor function and die within 2-5 years due to inability to breathe in most cases. There is currently no cure for ALS. Only one drug has been approved for the treatment of ALS, with a limited clinical benefit of slowing down the progression of disease. There are currently more than 70,000 ALS patients1,2 in the United States and Europe alone who would benefit from a new therapy. In previous work, Nanologica in collaboration with Professor Elena N Kozlova (Uppsala University) demonstrated sustained delivery of trophic factors for survival and functional differentiation of stem cells by using nanoporous silica particles.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|